GALT
HEALTHCAREGalectin Therapeutics Inc
$2.25+0.02 (+0.90%)PRE
Live · NASDAQ · May 9, Close
AI Insight
What's Moving GALT Today?
No stock-specific AI insight has been generated for GALT yet. Check back soon — insights are generated from recent news analysis.
52-Week Range
$1.21$7.13
$2.25
Fundamentals
Market Cap$139M
P/E Ratio—
EPS$-0.48
Dividend Yield—
Dividend / Share—
ROE-37.3%
Profit Margin—
Debt / Equity—
Trading
Volume383K
Avg Volume (10D)—
Shares Outstanding65.8M
GALT News
19 articles- Galectin Therapeutics (GALT) Upgraded to Buy: What Does It Mean for the Stock?Yahoo Finance·Apr 3, 2026
- Galectin Therapeutics Reports 2025 Financial Results and Provides Business UpdateYahoo Finance·Mar 31, 2026
- Galectin Therapeutics Strengthens Board of Directors with Appointment of Henry Brem, M.D.Yahoo Finance·Mar 17, 2026
- Galectin Therapeutics Highlights Belapectin Data in MASH Cirrhosis KOL Event, Eyes Next StepsMarketbeat·Mar 17, 2026
- Galectin Therapeutics to Host Virtual KOL Event to Discuss Belapectin Development Program for Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) Cirrhosis and Portal Hypertension, on March 10, 2026 at 12:00 PM ETYahoo Finance·Feb 26, 2026
- Galectin Therapeutics Inc.'s (NASDAQ:GALT) top owners are retail investors with 55% stake, while 20% is held by insidersYahoo Finance·Jan 22, 2026
- Galectin Therapeutics Receives FDA Written Response on Belapectin, Adds $10 Million Credit LineYahoo Finance·Dec 19, 2025
- Galectin Therapeutics Provides Regulatory Update Following FDA Written Response and Announces an Additional $10 Million Line of Credit from Richard E. Uihlein Sufficient to Cover Expected Expenditures Through March 2027Yahoo Finance·Dec 19, 2025
- Galectin Therapeutics Reports Financial Results for the quarter ended September 30, 2025, and Provides Business UpdateYahoo Finance·Nov 14, 2025
- Galectin Therapeutics Presented NAVIGATE Trial Results at the American Association for the Study of Liver Diseases (AASLD) 2025 Annual MeetingYahoo Finance·Nov 10, 2025
- Galectin Therapeutics to Present at the American Association for the Study of Liver Disease (AASLD) Liver Meeting 2025Yahoo Finance·Oct 7, 2025
- Galectin Therapeutics Inc. (GALT) Surges on Promising Belapectin Trial Data and Strong FinancialsYahoo Finance·Sep 23, 2025
- Galectin Therapeutics to Present at the H.C. Wainwright 27th Annual Global Investment ConferenceYahoo Finance·Sep 2, 2025
- Galectin Therapeutics Inc.'s (NASDAQ:GALT) top owners are individual investors with 54% stake, while 21% is held by insidersYahoo Finance·Aug 15, 2025
- Galectin Therapeutics Reports Financial Results for the Quarter Ended June 30, 2025 and Provides Business UpdateYahoo Finance·Aug 14, 2025
- Galectin Therapeutics Announces New $10 Million Credit Line from Richard E. Uihlein, Sufficient to Cover Expected Expenditures Through June 2026Yahoo Finance·Jul 9, 2025
- Galectin Therapeutics to Host Virtual KOL Event to Discuss Belapectin for Treatment of MASH Cirrhosis and Portal HypertensionYahoo Finance·Jun 10, 2025
- Galectin Therapeutics Reports Financial Results for the Quarter Ended March 31, 2025 and Provides Business UpdateYahoo Finance·May 15, 2025
- Galectin Therapeutics Presented NAVIGATE Trial Results at the European Association for the Study of the Liver (EASL) 2025 CongressYahoo Finance·May 12, 2025
All 19 articles loaded
Price Data
Open$2.31
Previous Close$2.23
Day High$2.38
Day Low$2.19
52 Week High$7.13
52 Week Low$1.21
52-Week Range
$1.21$7.13
$2.25
Fundamentals
Market Cap$139M
P/E Ratio—
EPS$-0.48
Dividend Yield—
Dividend / Share—
ROE-37.3%
Profit Margin—
Debt / Equity—
Trading
Volume383K
Avg Volume (10D)—
Shares Outstanding65.8M
About Galectin Therapeutics Inc
Galectin Therapeutics Inc., a clinical-stage biopharmaceutical company, is dedicated to the research and development of therapies for fibrotic, cancerous and other diseases. The company is headquartered in Norcross, Georgia.
HEALTHCAREBIOTECHNOLOGY
Company Details
Security TypeStock
ExchangeNASDAQ
CurrencyUSD
Round Lot—
SICBIOTECHNOLOGY
CIK—
Composite FIGI—
Share Class FIGI—